| Autor: |
Yasmine Oladele Hardy, Elena Libhaber, Emmanuel Ofori, Divine Aseye Yao Amenuke, Samuel Amoabeng Kontoh, James Amoah Dankwah, Rita Larsen‐Reindorf, Caleb Otu‐Ansah, Kojo Hutton‐Mensah, Ebenezer Dadson, Sheila Adamu, Kofi Akyerekoh, Fred Stephen Sarfo, Bernard Nkum |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Endocrinology, Diabetes & Metabolism, Vol 6, Iss 1, Pp n/a-n/a (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2398-9238 |
| DOI: |
10.1002/edm2.391 |
| Popis: |
Abstract Background In sub‐Saharan Africa and particularly in Ghana, there is scarcity of published literature specifically on the impact of DM on outcomes in COVID‐19 patients. Based on the difference in genetic makeup and demographic patterns in Africans compared to the Western world and with the rising burden of DM and other non‐communicable diseases in Ghana there is a need to define the impact DM has on persons with COVID‐19. This would ensure adequate risk stratification and surveillance for such patients as well as appropriate scale up of therapeutic management if needed. Aims This single‐center study describes the clinical and laboratory profile and outcomes of COVID‐19 in‐patients with type 2 diabetes mellitus (DM) in Ghana. Materials and Methods Retrospective analysis was undertaken of the medical records of adults with COVID‐19 hospitalized at a facility in Ghana from March to October 2020. Clinical, laboratory and radiological data and outcomes were analysed. Comparisons between COVID‐19 patients with DM and non‐diabetics were done with an independent t‐test or a Mann–Whitney test when normality was not attained. Odds ratios (95% CI) were calculated using univariate logistic regression. Results Out of 175 COVID‐19 patients, 64 (36.6%) had DM. Overall mean age was 55.9 ± 18.3 years; DM patients were older compared to non‐diabetics (61.1 ± 12.8 vs. 53.0 ± 20.2 years, p = .049). Compared to non‐diabetics, diabetics were more likely to have higher blood glucose at presentation, have hypertension, be on angiotensin 2 receptor blockers [OR, 95% CI 3.3 (1.6–6.7)] and angiotensin converting enzyme inhibitors [OR, 95% CI 3.1 (1.3–7.4)]; and be HIV negative (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text